Reuters logo
BRIEF-Pfizer announces outcome of FDA advisory committee meeting for Sutent
September 19, 2017 / 5:24 PM / 2 months ago

BRIEF-Pfizer announces outcome of FDA advisory committee meeting for Sutent

Sept 19 (Reuters) - Pfizer Inc:

* Pfizer announces outcome of FDA advisory committee meeting for Sutent in patients at high risk of recurrent renal cell carcinoma after surgery

* Says ‍FDA decision on whether or not to approve SNDA is anticipated by January 2018​

* Says ‍FDA voted 6 in favor, 6 against benefit-risk profile for Sutent as adjuvant treatment of adults at high risk of recurrent RCC after nephrectomy​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below